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Spinocerebellar ataxias 6 and 7 (SCA6 and SCA7) are neurodegenerative disorders caused by expansion of
CAG repeats encoding polyglutamine (polyQ) tracts in CACNA1A, the alpha1A subunit of the P/Q-type calcium
channel, and ataxin-7 (ATXN7), a component of a chromatin-remodeling complex, respectively. We hypoth-
esized that ﬁnding new protein partners for ATXN7 and CACNA1A would provide insight into the biology of
theirrespectivediseasesandtheirrelationshiptootherataxia-causingproteins.Weidentiﬁed118proteininter-
actionsforCACNA1AandATXN7linkingthemtootherataxia-causingproteinsandtheataxianetwork.Tobegin
tounderstandthebiologicalrelevanceoftheseproteininteractionswithintheataxianetwork,weusedOMIMto
identifydiseasesassociatedwiththeexpandedataxianetwork.WethenusedMedicarepatientrecordstodeter-
mine if any of these diseases co-occur with hereditary ataxia. We found that patients with ataxia are at 3.03-fold
greaterriskofthesediseasesthanMedicarepatientsoverall.Oneofthediseasescomorbidwithataxiaismacu-
lar degeneration (MD). The ataxia network is signiﬁcantly (P 5 7.37 3 10
25) enriched for proteins that interact
with known MD-causing proteins, forming a MD subnetwork. We found that at least two of the proteins in the
MD subnetwork have altered expression in the retina of Ataxin-7
266Q/1 mice suggesting an in vivo functional
relationshipwithATXN7.Togetherthesedatarevealnovelproteininteractionsandsuggestpotentialpathways
that can contribute to the pathophysiology of ataxia, MD, and diseases comorbid with ataxia.
INTRODUCTION
Spinocerebellar ataxias (SCAs) are a class of neurodegenera-
tive disorders, characterized by the loss of balance, progress-
ive motor dysfunction and degeneration of the cerebellar
Purkinje cells (PC). Several SCAs are caused by the expansion
of unstable CAG repeats that encode a polyglutamine (polyQ)
tract in the respective protein (1). Outside of the CAG tract,
the proteins do not share homology. In all of the proteins,
the length of the polyQ tract correlates inversely with the
age of disease onset (reviewed in 2). The cellular and molecu-
lar pathophysiology underlying most of the SCAs is not under-
stood and many of the implicated proteins appear to be
functionally distinct (3–14). The common pathology in
these diseases, however, raised the possibility that common
molecular mechanisms might underlie the pathogenesis of
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proteins and to explore potential common molecular pathways
in the SCAs, our laboratory generated a protein interaction
network for 23 ataxia-causing proteins and their known inter-
acting partners using a high-throughput yeast two-hybrid
(Y2H) screen (15). The ataxia network (interactome) success-
fully led to the identiﬁcation of shared pathways and key inter-
actions relevant to the pathophysiology of ataxia (16–26). One
of the proteins identiﬁed in the original screen and investi-
gated further by our lab was RNA binding motif protein 17
(RBM17). RBM17 is an RNA binding protein that functions
in a spliceosome complex (27,28). In vivo studies demon-
strated a molecular role for RBM17 in SCA1 gain of function
(18). Together these ﬁndings highlight the utility and quality
of the screen and the ataxia network.
However, a few of the bait proteins failed to identify many
interacting partners (15). The proteins that failed had, on
average, fewer different bait fragments, and many were only
full-length baits. Two of the proteins that failed to identify
interactors in the original screen were CACNA1A (zero inter-
actors) and ataxin-7 (three interactors), the disease causing
proteins for SCA6 and SCA7, respectively.
Patients with SCA6 have dysarthria, oculomotor abnormal-
ities and an ataxic gait. SCA6 is caused by an expansion of a
CAG repeat in CACNA1A, a pore-forming subunit of the
P/Q-type calcium channels. There are three reported isoforms
of CACNA1A that result from alternative splicing at the
C-terminus; however, two of these, MPI and MPc, make up
99% of the transcripts (8,29). These two splice variants
differ in the splice acceptor site for the ﬁnal exon such that
MPI includes exon 47 and the CAG coding repeat is translated
into a polyglutamine (polyQ) tract in the cytoplasmic tail of
the protein, whereas MPc splices to an immediate stop
codon, resulting in a shorter cytoplasmic tail lacking the
polyQ tract. Since the polyQ tract is in the cytoplasmic tail
of the MPI isoform, it is readily available for protein–
protein interactions. Furthermore, data from Kordasiewicz
et al.( 30) suggest that the cytoplasmic tail of CACNA1A
can be cleaved and translocated to the nucleus, possibly indi-
cating a novel function for this protein distinct from its role as
a channel subunit.
Patients with SCA7 have macular degeneration (MD) in
addition to ataxia (31,32). SCA7 is caused by an expansion
of a coding CAG repeat near the N-terminus of ataxin-7.
Ataxin-7 is evolutionarily conserved with the yeast SAGA
complex component, Sgf73, particularly in two blocks
within the N-terminal portion of the respective proteins
(9,33–35). Ataxin-7 is a component of a STAGA/TFTC
histone acetyl transferase complex (9). In mammals,
glutamine-expanded ataxin-7 interferes with the proper func-
tion of the complex and leads to misregulation of rod photo-
receptor gene expression (9,36,37). Interestingly, in mouse
and human tissues, ataxin-7 is localized in both the nucleus
and cytoplasm and it can shuttle between the nucleus and
the cytoplasm in live cells (38–47). There is currently no
known functional role for ataxin-7 in the cytoplasm.
We hypothesized that identifying protein partners of
CACNA1A and ataxin-7 will provide insight into SCA6 and
SCA7 pathogenesis. Boxem et al.( 48) demonstrated that
using fragments in an Y2H screen increases the sensitivity
without reducing the speciﬁcity. Therefore, we hypothesized
thatusingpartialsegmentsofthecodingsequencesofbothwild-
type and polyQ expanded CACNA1A and ataxin-7 would
increase the likelihood of identifying interacting partners.
Additionally, we hypothesized that the expanded ataxia
interactome could provide insight into ataxia pathogenesis.
We present data here integrating the ataxia interactome with
patient medical records to uncover molecular associations
for diseases comorbid with ataxia. Furthermore, we show
that some of the proteins predicted to be relevant for one
comorbid disease, MD, are altered in a mouse model of
SCA7 exhibiting MD.
RESULTS
Identiﬁcation of novel ataxin-7 and CACNA1A
interacting partners
To identify interacting partners for CACNA1A and ataxin-7,
we generated 28 baits representing overlapping fragments of
each protein (Fig. 1 and Supplementary Material, Table S1).
The fragments of ataxin-7 were chosen based on known evo-
lutionarily conserved or functional domains (9,38,49).
CACNA1A baits were generated from the cytoplasmic tail
of both isoforms. For the MPI isoform, we used multiple
polyQ lengths; 11Q is common in wild-type alleles (one bait
was 15Q for the wild-type length due to expansion during
cloning), 23Q is disease-causing and 72Q is hyper-expanded
(8,29). For clarity, throughout this manuscript, we refer to
these as MPI-11Q, MPI-23Q and MPI-72Q, respectively,
and MPI refers to this isoform regardless of polyQ length.
All of the baits were fused to the DNA binding domain of
Gal4 using the Invitrogen Gateway system and were used in
a high-stringency Y2H screen against an adult human brain
cDNA library. We identiﬁed 152 unique interactions with
CACNA1A_MPI, CACNA1A_MPc and ataxin-7 (Supplemen-
tary Material, Table S2). For CACNA1A, we identiﬁed 59
interactors with the MPI isoform and 44 with the MPc
isoform; for ataxin-7, we identiﬁed 49 interactors. Seventeen
prey proteins were shared by both CACNA1A and ataxin-7,
and 17 prey proteins interacted with both CACNA1A iso-
forms; in many instances, we identiﬁed multiple independent
clones of the same protein. Thus, a total of 118 different
prey proteins were identiﬁed.
We next sought to recapitulate the interactions in mamma-
lian cells. We therefore tagged the bait and prey proteins with
GST and myc, respectively, and tested 47 of 152 of the
Y2H-based interactions using glutathione-sepharose afﬁnity
co-puriﬁcations (GST-APs) in HEK293T cells (15,50,51).
Speciﬁcally, we were able to recapitulate the interactions for
78.7% of the protein pairs tested (Fig. 2 and Supplementary
Material, Table S2). This rate of reproducibility of Y2H inter-
actions in mammalian cells is similar to that seen in other
studies and conﬁrms the high quality of the screen (15,50,51).
CACNA1A interacts with several proteins in an
isoform-speciﬁc manner
Given that only one of the two predominant isoforms of
CACNA1A contains the disease-causing CAG tract, we
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isoform, MPI, may be particularly relevant to pathogenesis.
Therefore, we further explored the CACNA1A interactions,
speciﬁcally searching for proteins that interact in a polyQ
length-dependent and/or isoform speciﬁc manner. In the
initial Y2H screen, we identiﬁed 44 different protein inter-
actions with MPc, the short isoform, and 59 interactions
with MPI, the polyQ containing isoform. Of these, 17 were
identiﬁed by both classes of baits. Since the screen was not
saturated, some of the interactions may have been found
only with one isoform by chance. Cross-testing all of the
interactions that were unique to each isoform by a yeast
mating assay against the other isoform revealed that 71 of
86 proteins interacted with both isoforms, whereas 15 of the
interactions were exclusive to the MPI (glutamine-containing)
isoform in yeast. None of the proteins identiﬁed was unique to
MPc, consistent with MPc containing domains that are also
present in MPI (Fig. 1B).
We then speciﬁcally tested the 15 MPI partners by GST-AP
to explore these interactions in a mammalian system (Table 1,
Fig. 3). Of the 15, 5 are not expressed at detectable levels in
this system and therefore could not be evaluated. Of the
Figure 1. Baits used to identify proteins that interact with ataxin-7 and CACNA1A. (A) Ataxin-7 baits. Conserved and functional domains are indicated with
boxes and an inverted triangle indicates the polyQ tract (10 and 52Q were used). Amino acid range, transformation efﬁciency and the number of identiﬁed pro-
teins are given for all the constructs in Supplementary Material, Table S1. Though all had greater than 7.56 × 10
5 transformation efﬁciency, not all baits found
interacting partners. (B) CACNA1A baits. The full-length protein is shown with the transmembrane domains and polyQ tract as indicated. The C-terminus of the
protein (cytoplasmic tail) is shown in greater detail with the amino acid indicated for the beginning of each fragment. In the MPI isoform, the inverted triangle
indicates the polyQ tract (11, 23 and 72Q were used for each construct).
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system, 6 proved to interact with both CACNA1A isoforms
in mammalian cells (Fig. 3A and B). Three of these,
RBM12B, LPHN1 and SIAHBP1, preferentially interact
with the pathogenic MPI-23Q and hyper-expanded MPI-72Q
GST fusion and also with MPc, but not with the wild-type
length MPI-11Q construct. This suggests that the polygluta-
mine expansion within the MPI isoform may cause aberrant
protein–protein interactions with MPc interacting partners.
Another 3, of the 10 proteins tested (ABI1, BZRAP1,
YLPM1), recapitulate the Y2H interactions and interact only
with the MPI isoforms (Fig. 3C and D). Furthermore, ABI1
and YLPM1 preferentially interact with the disease-causing
MPI-23Q and hyper-expanded MPI-72Q polyQ form and not
with the wild-type length MPI-11Q.
Analysis of the ataxia network including CACNA1A
and ataxin-7 partners
To learn about the biological properties of the new ataxia
network, it is necessary to analyze its topological properties
as they typically bring useful insight into organizational prin-
ciples of biological networks (52,53). We explored the
network properties of the ataxia interactome, including its
degree distribution, which is the distribution of the number
of proteins each protein interacts with, the identiﬁcation of
proteins with high betweenness centrality (a measure of the
importance of a node to the overall network) and enrichment
of ataxia subnetworks (54). Our previously published
network looked at the degree distribution of an expanded
network which included the literature-curated interactions to
allow comparison of the degree distribution to that of other
interactome studies of model organisms (15). Here we gener-
ated the ataxia interactome solely based on data generated
from the Y2H screen we performed (Fig. 4) and did not
include literature-curated interactions to avoid biases emer-
ging from well-studied proteins (55). This ataxia interactome
has a noisy degree distribution even with the logarithmic
binning due to less rich statistics compared with the
literature-expanded network. Yet, the distribution is still con-
sistent with a power law, in agreement with previously found
scaling exponent 22.2 (Supplementary Material, Fig. S1)
indicating the importance of hubs in the ataxia network.
The proteins with the highest betweenness centrality in the
interactome tend to act as bridges connecting functional
modules (56). In this network, CACNA1A emerges as one of
these proteins. The difference between the previously published
ataxia interactome and the new updated network is due to the
large number of newly identiﬁed interactors for CACNA1A.
This result emphasizes the importance of multiple, overlapping
Figure 2. Representative western blots of GST-APs recapitulating the inter-
actions identiﬁed for various myc-tagged prey proteins. Blotting antibodies
are anti-myc and anti-GST as indicated. (A) Ataxin-7 interactors. (B) CAC-
NA1A_MPc interactors.
Table 1. CACNA1A isoform speciﬁc interactions identiﬁed by Y2H and
recapitulated by GST-AP in mammalian cells
Entrez
ID
HGNC
Symbol
MPc Wild-type MPI-
11Q, or MPI-15Q
Pathogenic MPI-23Q
or MPI-72Q
Y2H
10006 ABI1 No ++
9256 BZRAP1 No ++
114897 C1QTNF1 No ++
9793 CKAP5 No + No
51232 CRIM1 No + No
25822 DNAJB5 No + No
8997 KALRN No ++
22859 LPHN1 No + No
389677 RBM12B No ++
23504 RIMBP2 No ++
22827 SIAHBP1 No + No
8848 TSC22D1 No + No
7407 VARS No + No
56252 YLPM1 No ++
353355 ZNF233 No + No
GST-AP
10006 ABI1 No No +
9256 BZRAP1 No ++
51232 CRIM1 ++ +
25822 DNAJB5 + No No
22859 LPHN1 + No +
389677 RBM12B + No +
22827 SIAHBP1 + No +
8848 TSC22D1 ++ +
7407 VARS ++ +
56252 YLPM1 No No +
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Overall, the expanded network properties are statistically
unchanged from the earlier network by the addition of two new
hubs (compared in Supplementary Material, Table S3) (15).
One of the most useful analyses in terms of understanding
the biology of the network is the identiﬁcation of disease path-
ways by locating subnetworks or modules within the overall
network (57–61). We searched for proteins linking pairs of
ataxia-causing proteins that we call ‘ataxia triples.’ A
protein in a triple directly interacts with two different ataxia-
causing proteins in the form: Ataxia-protein1–Interactor–
Ataxia-protein2. All of the new triples that did not appear in
the previous network included CACNA1A and/or ataxin-7 as
one of the ataxia proteins, suggesting that CACNA1A and
ataxin-7 are linked to other ataxia-causing proteins through
multiple interacting partners. There are 116 ataxia triples in
our network compared with 53 and 63 in the previous Y2H-
and literature-expanded ataxia interactomes, respectively
(15). We calculated the signiﬁcance of the observed number
of triples, by randomizing the ataxia interaction network and
preserving its degree distribution. With 1000 random realiz-
ations, on average, we observed 18 (+ 9) triples, which
renders the number of triples, 116, in our network highly sig-
niﬁcant (P , 0.001). The large number of links from ataxia-
causing proteins most likely explains the large number of
triples compared with the randomized networks. It is also
useful to compare the number of triples in networks con-
structed from proteins associated with a phenotypically
diverse group of disorders. This control, while focusing on
disease proteins, removes biases for a particular disease phe-
notype and permitted us to analyze the extent to which the
phenotype-based ataxia network has unusual topological prop-
erties. The number of triples in the ataxia interactome was sig-
niﬁcantly higher (P , 0.005) than phenotypically diverse
networks with a mean of 31 triples, suggesting the importance
of these triples in ataxia pathology (15).
Gene-disease associations and comorbidity analysis
The interaction network we mapped experimentally is based on
screening with proteins involved in one common phenotype,
ataxia, and contains many proteins of diverse functions. We
hypothesized that if the protein interactions in the ataxia
network are biologically relevant and relevant to the pathogen-
esisofataxia, thenother diseases associated withproteins inthe
network are more likely to occur in patients with ataxia. There-
fore, using the network data together with Medicare patient
records, we asked three questions. First, we asked whether
patients with ataxia are at an increased risk of having any
other diseases compared with other Medicare patients;
Figure 3. Representative western blots of GST-APs for proteins that interacted with the CACNA1A_MPI but not CACNA1A_MPc isoform by Y2H mating
assay (Table 1). The myc-tagged prey and GST-tagged baits are indicated (empty vector, MPc or MPI polyQ length). Blotting antibodies are anti-myc and
anti-GST as indicated. (A) The myc-TSC22D1 interaction is neither isoform nor polyQ length dependant in mammalian cells. (B) The myc-RBM12B interaction
with CACNA1A is not isoform speciﬁc, but for MPI is polyQ length dependant, interacting with the disease-causing 23Q and hyper-expanded 72Q but not the
wild-type 11Q baits. (C) The myc-BZRAP1 interaction with CACNA1A is isoform, but not polyQ length dependant. (D) The myc-YLPM1 interaction with
CACNA1A is both isoform and polyQ length dependant.
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in the ataxia interactome; and ﬁnally, what relationships exist
between proteins implicated in the same diseases?
We ﬁrst performed comorbidity analysis in the large set of
Medicare patient medical history data in the form of ICD-9
codes from 13 million patients. We aimed to make the analysis
as speciﬁc to the hereditary ataxias as possible. Therefore, we
removed records from both our patient and control group with
ICD codes corresponding to toxic effects from non-medical
substances (codes 980–989). We then deﬁned the ataxia
patient population by only including ICD-9 codes correspond-
ing to speciﬁc ataxia diagnoses therefore excluding most non-
degenerative ataxias (see Materials and Methods for ICD-9
codes corresponding to ataxia). We also removed ataxia
patients with documented alcoholism since chronic alcohol
abuse can cause ataxia. In our medical history data set, we
identiﬁed 11 265 patients who have a diagnosis of ataxia
meeting our criteria and 13 022 828 controls. By looking for
diseases that appear more often in ataxia patients than in the
patient population as a whole, we identiﬁed diseases that are
comorbid with ataxia. We measured relative risk based on
the number of occurrences of any one diagnosis with ataxia,
and its prevalence in the ataxia and general patient populations
(see Materials and Methods). We found over 500 ICD-9 codes
with a relative risk of greater than 1.00 (Supplementary
Material, Table S4A). Overall, within the 99% conﬁdence
interval, the average relative risk among the ataxia patients
is 1.63, meaning that patients with ataxia are 1.63 times
more likely to also have any other diagnosis (a comorbid con-
dition) than Medicare patients without an ataxia diagnosis.
There are several built-in positive controls as well as limit-
ations of using ICD-9 codes. For example, nystagmus (code
379.50),aknownsymptomofcerebellardysfunction,hasarela-
tiveriskof25.1,meaningthisdiagnosisis25.1timesmorelikely
in a patient also diagnosed with ataxia. Conversely, despite our
effortstousestrictcriteriatoclassifypatients,alimitationofthis
method is the inclusion of non-genetically caused ataxia due to
the diagnosis/billing codes used. For example, although we
removed patients with documented toxic substance exposure
and alcoholism, some cases of alcoholic ataxia are possibly
included and thus there is high relative risk of alcohol-induced
persisting amnestic disorder (code 291.1) with a relative risk
of 5.3, which is not due to a common molecular pathway, but
rather to prolonged alcohol exposure. However, assessing the
Figure 4. Ataxia interaction network. Red nodes are ataxia-causing proteins. CACNA1A and ataxin-7, screened in this study, are outlined in orange. Newly
identiﬁed interactors are light blue and previously reported interactors are dark blue. The properties of this network are described in Supplementary Material,
Figure S1 and Table S3.
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introduces investigator bias. Ataxia is generally an outpatient
condition and patients may have been seeking medical care
for some other diagnosis, which may or may not be related to
their ataxia; however, we cannot infer a priori which diagnoses
are directly related.
We thereforeused gene-disease associationsandcomorbidity
analysis to relate proteins in the ataxia interaction network to
diseasephenotypesandtoanalyzewhethermolecularlevelgene-
diseaserelationshipsareobservedinthepopulation(62–64).To
relate the ataxia protein–protein interaction network to popu-
lation disease patterns, we interrogated the ataxia network for
proteins with links to disease phenotypes by searching the
Online Inheritance in Man (OMIM) database (http://www.
ncbi.nlm.nih.gov/omim/) for known gene-disease associations
and we generated an overlap list of diseases that are represented
in the ataxia network and appear in ataxia patients. We used this
overlap list to assessthe relative risk forpatientsdiagnosed with
ataxia to also have a disease whose associated protein is present
in the ataxia network (Supplementary Material, Table S5).
Accounting for a molecular relationship this risk is 3.03, which
is signiﬁcantly higher than the general comorbidity risk of 1.63
(SupplementaryMaterial,TableS4B).Thisenrichmentindicates
that detailed protein interaction maps can shed light into
population disease patterns. Furthermore, we can use the list of
diseases that occur more often in ataxia patients and have
known molecular causes to investigate the biological origin of
the comorbidity relationships between diseases.
Macular degeneration associated proteins are tightly
linked to one another and form a subnetwork
Interestingly, although not entirely unexpected, MD (code
362.50) was 2.7 times more likely to be diagnosed in ataxia
patients than controls. Additionally, other similar visual diag-
noses were also overrepresented in patients (Supplementary
Material, Table S6). We were particularly intrigued that MD
was comorbid with ataxia since it is considered a unique
feature of SCA7 and we wanted to further understand the mol-
ecular relationship between ataxin-7 and other MD-causing
proteins and to verify the comorbidity analysis. We hypoth-
esized that our network was enriched for proteins associated
with retinal degeneration. We therefore used the OMIM data-
base to identify proteins associated with macular or retinal
degeneration or dystrophy (see Materials and Methods for
search terms). Surprisingly, of the 33 proteins that met these
criteria, only ﬁbulin 5 (FBLN5) and EGF-containing ﬁbulin-
like extracellular matrix protein 1 (EFEMP1) appeared in
the ataxia network. Ataxin-7 is not included in the OMIM
database as an MD-associated gene, despite the fact that
glutamine-expanded ataxin-7 causes MD (31,32,39,43,45).
When we did not ﬁnd enrichment for retinal
degeneration-associated proteins as we expected, we investi-
gated the proteomic relationship of MD-associated proteins
(FBLN5, EFEMP1 and ATXN7) within the ataxia interac-
tome, hypothesizing that the relationships between these pro-
teins may provide insights into retinal degeneration. We
looked for MD subnetworks, ﬁnding two MD triples in the
ataxia network where an MD triple is deﬁned as three interact-
ing proteins in the form: MD protein1–Interactor–MD
protein2 and where the three MD proteins are FBLN5,
EFEMP1 and/or ATXN7. Interestingly, we identiﬁed 80 MD
quadruples (MD protein1–Interactor–Interactor–MD
protein2) (Fig. 5A). Ataxin-7, owing to being a hub, is
central to the MD network and removing it results in a col-
lapse of the MD subnetwork (Fig. 5B).
In order to determine the signiﬁcance of the number of
observed quadruples, we measured the number of quadruples
Figure 5. (A) MD subnetwork endpoints are ATXN7, EFEMP1 and FBLN5, indicated in orange. Ataxia-causing proteins are red. New interactors are in light
blue and interactors also present in the earlier ataxia network are in dark blue. There are 80 quadruples involving 32 proteins (Table 2). All binary interactions
recapitulated by GST-APs (after testing 20 pairs) are indicated with red lines. (B) MD subnetwork is highly dependent on ATXN7, when the ATXN7 node is
removed the subnetwork collapses.
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we found 0.48 quadruples rendering the 80 observed MD quad-
ruples in the ataxia interaction network highly signiﬁcant (P ¼
7.37 × 10
25). Since ataxin-7 was a bait protein with a large
number of interacting partners, a more strict control would be
to ﬁnd the quadruples between prey proteins and ataxia (bait)
proteins. In this case, we found 2.56 such quadruples on
average, again signiﬁcantly less than the 80 we observed
based on the three MD-causing proteins (P ¼ 0.000596).
Thus, this high number of observed quadruples indicates that
the three proteins known to be involved in MD are highly con-
nected. Since the proteins in the MD subnetwork are quite
diverse, we examined the protein pairs in the network and
found that of the 83 interacting pairs 17 had been validated by
GST-APs in the course of our validation of this Y2H screen
and the previously published data in Lim et al.( 15).
Given the signiﬁcant enrichment of MD quadruples within
the ataxia network, we hypothesized that these interactors are
possible candidates for MD-causing or modifying loci or other-
wise important in establishing or maintaining retinal health.
All MD subnetwork proteins are expressed in retina
Since our screening used an adult brain cDNA library, we ﬁrst
tested the hypothesis that the proteins included in the MD sub-
network are also expressed in the retina. Literature searches
revealed that 31 of the 32 MD quadruple proteins (or their para-
logues)demonstrateretinalexpressionbyeitherRNAorprotein
detection methods (Table 2)( 65–72). The remaining protein,
GFI1B, a transcriptional repressor, was used as a bait protein
in the earlier interactome studies and thus is a hub within the
MD subnetwork; therefore, it was essential that we validate its
retinal expression. We ﬁrst used commercial human retina
polyA RNA for quantitative real-time PCR and detected
GFI1B transcript (data not shown). We also sought evidence
of GFI1B protein expression using immunoﬂuorescence in
wild-type mouse retina. We found that GFI1B is expressed
most prominently in the outer nuclear layer (ONL) (Fig. 6A).
Takentogether,theseresultsdemonstratethatalloftheproteins
in the MD subnetwork are expressed in the retina.
Given that our screen was not performed using a retina
cDNA library, nor was the screen saturated and given
central importance of ataxin-7 in the MD subnetwork, we con-
sidered that other ataxin-7 interactors might also be important
in retinal health. We thus expanded our literature review and
found that the 27 additional ataxin-7 interactors are all
expressed in the eye or retina. Overall, we show that all 59
ataxin-7 interactors or MD quadruple components are
expressed in the mammalian retina; interestingly, some of
the genes map to loci previously associated with familial
retinal degeneration (Table 2), suggesting they may be candi-
dates for disease genes, although overall we would predict the
MD-associated loci would be genetic modiﬁers of retinal
health (31,32,47,65–99).
Ataxin-7 knock-in mice display altered expression of some
interacting partners in retina
We next hypothesized that some of the ataxin-7 interactors
and/or MD quadruple proteins would be altered in the retina
of a previously characterized SCA7 knock-in mouse model,
Ataxin-7
266Q/+ (39). In a mixed genetic background, visual
dysfunction begins around 5 weeks of age and ataxin-7 micro-
aggregates are seen beginning at 8–10 weeks of age with more
and larger inclusions by 15 weeks (39). However, as the mice
have been backcrossed to a pure C57BL6/J background, the
Ataxin-7
266Q/+ mice die at 10–11 weeks of age and inclusions
remain very small.
To validate the functional relevance of the MD subnetwork
in vivo, we examined the expression of some MD subnetwork
components by immunoﬂuorescence in 5-, 8- and 10-week-old
Ataxin-7
266Q/+ retina and wild-type littermate controls. Unfor-
tunately, in vivo mouse ataxin-7 protein studies are limited by
a lack of an antibody that recognizes normal expression of
either the wild-type mouse or knock-in protein, precluding
co-localization studies until after protein inclusions have
formed.
We therefore used RNA in situ hybridization (ISH) to
uncover Atxn7 expression in the ONL, inner nuclear (INL)
and ganglion cell layers (GCL) of wild-type C57BL6/J
mouse retinal sections (Fig. 6B). These data support previous
data from other groups using immunostaining in SCA7 patient
and control retina tissue that ﬁnd ataxin-7 expression in these
same retinal layers (40,46,70,100). Furthermore, Cancel et al.
(40) and Einum et al.( 100) demonstrate ataxin-7 staining in
control patient retina in the inner plexiform layer (IPL),
speciﬁcally in both cytoplasm and processes of the ganglion
cells, the outer plexiform layer (OPL) and also in the inner
and outer segments of the rods and cones. Thus, our ISH
data and patient protein data taken together demonstrate that
ataxin-7 is normally expressed throughout the retina.
We next randomly selected 7 of the 59 MD subnetwork and/
or ataxin-7 interacting proteins for immunoﬂuorescence
studies. We used retina from wild-type and Ataxin-7
266Q/+ lit-
termates collected at 5, 8 and 10 weeks of age and immunos-
tained for TRIM27, TRIM23, GRN, RAD23A, TRIM54,
SIAH1 and CARD10 protein expression.
TRIM27 is a zinc ﬁnger protein that is reported to be a tran-
scriptional repressor (101,102); however, similarly to ataxin-7,
in some cell types TRIM27 is reportedly cytoplasmic (103). In
mouse retinal sections, TRIM27 is strongly expressed in the
ONL (Fig. 7A). Additionally, it is expressed in the outer seg-
ments of the photoreceptors, INL and GCL (data not shown).
At 5 weeks, staining levels in wild-type and Ataxin-7
266Q/+
retina are approximately equivalent. However, in both geno-
types, staining increases with age in the nuclear layers. The
increase is more obvious in knock-in retina such that at
10 weeks the staining is many times brighter in the ONL
than either earlier Ataxin-7
266Q/+ or age-matched wild-type
retina. Importantly, the alteration in TRIM27 expression
occurs at a protein level as Trim27 RNA is not altered in
Ataxin-7
266Q/+ retina by qRT–PCR (data not shown).
TRIM23 staining is in the OPL and IPL (Fig. 7B) in both
knock-in and wild-type retina. In contrast to TRIM27, which
is increased, TRIM23 immunostaining is reduced in
knock-in tissue, particularly in the OPL. Given that the
Ataxin-7
266Q/+ mice have progressive retinal degeneration
we co-labeled with anti-calbindin, a marker of horizontal
and amacrine cells, to better visualize the OPL (Fig. 7C). Flu-
orescence of the TRIM23 in Ataxin-7
266Q/+ tissue was lower
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Human
symbol
Entrez
ID
Mouse
symbol
Entrez
ID
Expression studies Human mapped
loc.
Overlapping RetNet
unmapped?
ACTN1
a 87 Actn1 109711 Blackshaw et al.( 65) 14q22–q24 No
ACTN2 88 Actn2 11472 Schulz et al.( 72) 1q42–q43 No
ACTN4 81 Actn4 60595 Schulz et al.( 72) 19q13 MCDR5
ADAM33 80332 Adam33 110751 UniGene Hs.173716 20p13 No
AGRN
a 375790 Agrn 11603 Blackshaw et al.( 65) 1p36.33 LCA9
ATN1
a 1822 Atn1 13498 Blackshaw et al.( 65), Zhang et al.( 71) 12p13.31 No
ATXN1L
a 342371 Atxn1L 52335 Blackshaw et al.( 65) 16q22.2 No-FHASD close
ATXN7
a 6314 Atxn7 246103 Stro ¨m et al.( 70) and this study 3p21.1–p12 Yes-itself
CACNA1A
a 773 Cacna1a 12286 Xu et al.( 87) and Blackshaw et al.( 65) 19p13.2–p13.1 No
CARD10 29775 Card10 105844 Schulz et al.( 72) 22q13.1 OPA5 and VRD1
CEP70 80321 Cep70 68121 Blackshaw et al.( 65) 3q22–q23 No
CEP72 55722 Cep72 74470 Blackshaw et al.( 65) 5p15.33 MCDR3
COG6 57511 Cog6 67542 Blackshaw et al.( 65) 13q13.3 No
CRIM1
a 51232 Crim1 50766 Lovicuet al.( 78), Kinna et al.( 98), Pennisi et al.
(81)
2p21 No
EFEMP1
a 2202 Efemp1 216616 Stone et al.( 84) 2p16 No
EFEMP2
a 30008 Efemp2 58859 Blackshaw et al.( 65) 11q13 VRNI
FBLN5
a 10516 Fbln5 23876 Blackshaw et al.( 65) 14q32.1 ACHM1 and itself
FBN1 2200 Fbn1 14118 Blackshaw et al.( 65) 15q21.1 No
FN1 2335 Fn1 14268 Blackshaw et al.( 65), Siegert et al.( 83) 2q34 No
GFI1B
a 8328 Gﬁ1b 14582 This study 9q34.13 No
GOLGA2 2801 Golga2 99412 Blackshaw et al.( 65) 9q34.11 No
GOLGA3 2802 Golga3 269682 Blackshaw et al.( 65) 12q24.33 No
GPRASP1 9737 Gprasp1 67298 Blackshaw et al.( 65) Xq22.1 No
GRN
a 2896 Grn 14824 Blackshaw et al.( 65) 17q21.32 CORD4
JAG2
a 3714 Jag2 16450 Blackshaw et al.( 65) 14q32 ACHM1
KALRN
a 8997 Kalrn 545156 Unigene Hs.8004 3q21.1–q21.2 No
LAMB1
a 3912 Lamb1-1 16777 Sarthy and Fu (68) 7q22 No
LAMB2 3913 Lamb2 16779 Blackshaw et al.( 65) 3p21 No
LRSAM1 90678 Lrsam1 227738 Blackshaw et al.( 65) 9q33.3–q34.11 No
LTBP4
a 8425 Ltbp4 108075 Blackshaw et al.( 65) 19q13.1–q13.2 No-MCDR5 close
MATN2
a 4147 Matn2 17181 Fuchshofer et al.( 75) 8q22 OPA6
MEGF6
a 1953 Megf6 230971 Blackshaw et al.( 65) 1p36.3 LCA9
MEGF8
a 1954 Megf8 269878 Blackshaw et al.( 65) 19q12 No
MPRIP 23164 Mprip 26936 Blackshaw et al.( 65) 17p11.2 No
NELL1
a 4745 Nell1 338352 Piri et al.( 67) 11p15.2–p15.1 No
NELL2
a 4753 Nell2 54003 Blackshaw et al.( 65) 12q13.11–q13.12 No-CODA1 close
NOC2L
a 26155 Noc2l 57741 Hublitz et al.( 66) 1p36.33 LCA9
NUP62 23636 Nup62 18226 Blackshaw et al.( 65) 19q13.33 No-MCDR5 close
PICK1
a 9463 Pick1 18693 Blackshaw et al.( 65) 22q13.1 OPA5 and VRD1
PNMA1 9240 Pnma1 70481 Schulz et al.( 72) 14q24.3 ACHM1
PPP1R12C
a 54776 Ppp1r12c 232807 Schulz et al.( 72) 19q13.42 No
RABEP1 9135 Rabep1 54189 Blackshaw et al.( 65) 17p13.2 CACD
RAD23A 5886 Rad23a 19358 Blackshaw et al.( 65) 19p13.2 No
RERE
a 473 Rere 68703 Blackshaw et al.( 65) 1p36 LCA9
TRIM27
a 5987 Trim27 19720 Blackshaw et al.( 65) and this study 6p22 No
RNF31
a 55072 Rnf31 268749 Schulz et al.( 72) 14q11.2 MCDR4
SIAH1
a 6477 Siah1a 20437 Schulz et al.( 72), Yego and Mohr (89) 16q12 No
Siah1b 20438
SNX1 6642 Snx1 56440 Blackshaw et al.( 65) 15q22.31 No
SPRY1
a 10252 Spry1 24063 Blackshaw et al.( 65) 4q28.1 No
SSFA2 6744 Ssfa2 70599 Blackshaw et al.( 65) 2q31.3 No
THY1 7070 Thy1 21838 Blackshaw et al.( 65) 11q22.3–q23 No
TMEM25
a 84866 Tmem25 71687 Blackshaw et al.( 65) 11q23.3 No
TP53BP2 7159 Trp53bp2 209456 Blackshaw et al.( 65) 1q42.1 No
TRAF2 7186 Traf2 22030 Blackshaw et al.( 65) 9q34 No
TRIM23 373 Trim23 81003 Blackshaw et al.( 65) 5q12.3 No
TRIM54 57159 Trim54 58522 Blackshaw et al.( 65) 2p23.3 No
TXNDC11
a 51061 Txndc11 106200 Schulz et al.( 72) 16p13.13 No
UBQLN2 29978 Ubqln2 54609 Blackshaw et al.( 65) Xp11.23–p11.1 OPA2
VWF
a 7450 Vwf 22371 Blackshaw et al.( 65) 12p13.3 No
Entrez IDs and symbols are shown for both human and mice. Expression in the retina is based on the noted reference(s). RetNet (http://www.sph.uth.tmc.edu/
retnet/) loci that are overlapping or near (in case of unmatched markers) the chromosomal location of the indicated protein.
aProtein is in the MD subnetwork. The remainder interact with ataxin-7 but are not part of the MD subnetwork.
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sample preparation and imaging conditions. Thus, in order to
conﬁrm that the reduced ﬂuorescence was due to decreased
protein levels rather than cell loss, we scaled the intensity of
both the wild-type and Ataxin-7
266Q/+ images by a factor of
3× (Supplementary Material, Fig. S2). Scaling reveals that
the TRIM23 pattern is indeed preserved in both
Ataxin-7
266Q/+ and wild-type tissue, conﬁrming reduced
TRIM23 expression in the absence of cell loss. Additionally,
by qRT–PCR, Trim23 RNA levels are equivalent in wild-type
and Ataxin-7
266Q/+ retina thus demonstrating the reduction is
at the protein level (data not shown).
We found that both GRN and RAD23A are expressed in the
GCL and there are no differences between wild-type and
Ataxin-7
266Q/+ retina at the time points tested (Supplementary
Material, Fig. S3). Similarly, there are no differences in
TRIM54, expressed in the INL and ganglion cell nuclei.
SIAH1 appears similar between wild-type and Ataxin-7
266Q/+
retina, although it may be slightly brighter in wild-type
tissue. Finally, CARD10, a caspase recruitment domain
protein that is reportedly involved in GPCR signaling (104),
exhibits strong immunostaining in the outer segments in wild-
type mice but is not present in the Ataxin-7
266Q/+ mice at any
age. There is also weaker CARD10 staining of the ONL, in
a pattern similar to both GFI1B and TRIM27 staining. As
previously reported, Ataxin-7
266Q/+ mice exhibit early photo-
receptor degeneration. We therefore collected light micro-
scope images at the same time as CARD10 imaging; the
light images indicate that the difference in outer segment
staining is likely attributable to photoreceptor degeneration
(data not shown) (39).
Thus, the proteins we tested from the MD quadruples and
other ataxin-7 interactors are all expressed in the retina, con-
ﬁrming previous data from other labs. Additionally, at least
two, TRIM27 and TRIM23, demonstrate altered expression
in Ataxin-7
266Q/+ mouse retina compared with wild-type litter-
mates. Taken together the GST-AP validations, literature
support and in vivo expression data provide strong support
for the biological relevance and importance of the MD quad-
ruples identiﬁed in this study.
DISCUSSION
The earlier ataxia interactome provided new insight into the
pathogenesis of inherited ataxias (16–26), but it lacked inter-
actors for two SCA-causing proteins, CACNA1A and
ataxin-7. We hypothesized that using many fragments of the
two proteins rather than full-length proteins to rescreen an
adult human brain library in a highly stringent Y2H screen
would generate better coverage and yield more interactors.
By using 28 bait fragments, we identiﬁed 118 interactors for
CACNA1A and ataxin-7 and were able to include these inter-
actions in the ataxia interactome leading to a more expanded
ataxia-protein network. The fact that we were more successful
in ﬁnding binding partners using portions of the coding region
in comparison with the full-length proteins raises the possi-
bility that fragments might expose interaction domains that
are otherwise impossible to expose in a yeast system,
especially if certain cell-speciﬁc modiﬁcations are required
to uncover such surfaces.
CACNA1A has two predominant splice forms that are
expressed at roughly equal levels in wild-type mice.
However, in knock-in mice carrying a polyQ expansion of
either 14, 30 or 84 glutamines, there is a shift in the ratio of
expression such that the MPI isoform is expressed at up to
80% of the transcripts (29). In post-mortem SCA6 patient
brain samples, there was also an increased amount of the
MPI isoform compared with control brains (105). It is
unclear whether the increased prevalence of MPI is caused
directly by the expansion and how the shift in isoform stoichi-
ometry may alter disease pathogenesis. In this study, we used
the C-termini of two predominant CACNA1A isoforms, MPI
and MPc, as bait in an Y2H screen. Additionally, for the
MPI bait fragments, we used wild-type (MPI-11Q), disease-
causing (MPI-23Q) and hyper-expanded (MPI-72Q) polyQ
alleles. We identiﬁed interactors that are isoform speciﬁc
and also interactions that seem to make the MPI isoform
with an expanded polyQ tract act more similarly to the alterna-
tive, MPc splice form. Interactors that are exclusive to MPI
may mediate gain of function effects upon the expansion of
the polyQ tract, such that more available MPI results in
more association of these proteins. Given the altered MPc to
MPI ratio seen in both patients and mouse models of SCA6
and that in a SCA1 mouse model a change in stoichiometry
between two endogenous ataxin-1 containing complexes con-
tributes to neuropathology, we propose that differences in the
afﬁnity of interactors for either MPI or MPc could modify the
Figure 6. (A) GFI1B immunostaining in wild-type mouse retina. (B) RNA
in situ hybridization for Ataxin-7 and sense control as labeled.
Human Molecular Genetics, 2011, Vol. 20, No. 3 519SCA6 disease phenotype (18). Overall, we suggest that the
CACNA1A interactions that are isoform speciﬁc may be
important in the SCA6 disease process and that the newly
identiﬁed CACNA1A interacting partners may provide
insight into the molecular understanding of SCA6. Addition-
ally, the identiﬁcation of isoform-speciﬁc interactions for
CACNA1A raises the possibility that future protein-
interaction studies could provide additional insights when
the individual isoforms are considered as nodes instead of
including them together as a single protein, particularly
when only one isoform is associated with a disease.
Ataxin-7 is highly evolutionarily conserved. In fact, yeast
lacking the ataxin-7 homolog, Sgf73, can be rescued by wild-
type ataxin-7 expression (106). Our bait constructs took into
account the regions of highest homology across species and
paralogues. Interestingly, baits containing only the ﬁrst half
of the protein or the middle section were unable to identify
interacting partners. This is likely a result of two related
Figure 7. (A) TRIM27 immunostaining in the retina ONL of wild-type and Ataxin-7
266Q/+ mouse retina at 5, 8 and 10 weeks of age, as indicated. The knock-in
mice have increased expression of TRIM27, which is particularly evident at the later disease point. (B) TRIM23 immunostaining in wild-type and Ataxin-7
266Q/+
mouse retina at 5, 8 and 10 weeks of age, as indicated. The staining is more pronounced in the WT mice as they age compared with knock-in mice. (C) Calbindin
(green) and TRIM23 (red) are shown for wild-type and knock-in samples at 10 weeks.
520 Human Molecular Genetics, 2011, Vol. 20, No. 3factors; ﬁrst, the Y2H system that we used is highly stringent
and does not result in the high levels of overexpression seen in
some other screens. Second, the two baits that succeeded in
identifying interacting partners are the C-terminal fragments
that contain mostly regions not conserved in yeast, whereas
those fragments that failed predominantly contained the poly-
glutamine tract, block I and/or block II, conserved regions that
are known to be required for recruitment into yeast SAGA and
mammalian STAGA/TFTC complexes (9,33–35). We suspect
that in yeast, the interaction of ataxin-7 with SAGA com-
ponents might compromise the Y2H reporter assay. Interest-
ingly, block III is not found in Sgf73 and may have a
speciﬁc function aside from SAGA complex formation (9).
Furthermore, the successful baits begin near the reported
caspase-7 cleavage sites, suggesting a possible role for this C-
terminal protein fragment in vivo, although to date most
studies and antibodies have targeted the N-terminal cleavage
product (38,43,49). Despite being limited to only two success-
ful baits, we identiﬁed many novel ataxin-7 interactors and
revealed potentially interesting candidate partners.
Since the known role for ataxin-7 is as a STAGA/TFTC
component, we expected to ﬁnd ataxin-7 interactors related
to histone modiﬁcations and transcriptional regulation.
However, since the baits which successfully identiﬁed partners
do not contain the regions responsible for STAGA/TFTC
complex inclusion, it is not surprising that the proteins we
identiﬁed have other functions. Although ataxin-7 cytoplasmic
localization and nuclear-cytoplasmic shuttling have been
reported, most studies to date have focused on the role of
ataxin-7 in the nucleus. The ataxin-7 interactors we identify
include nuclear proteins with known roles in transcriptional
regulation and other proteins that are predicted to be cyto-
plasmic or secreted. Wild-type ataxin-7 was also found to
colocalize with BiP, a marker for the endoplasmic reticulum
in neurons, strengthening the likelihood that ataxin-7 has
other functions besides its role in the STAGA/TFTC com-
plexes (40). Thus, our studies provide a unique foundation
for future studies to uncover novel roles of ataxin-7.
Our studies of CACNA1A and ataxin-7 interacting partners
lead to an expansion of the ataxia interactome (15). We then
used the updated ataxia interactome as a tool for exploring dis-
eases comorbid with ataxia, hypothesizing that comorbid con-
ditions would be associated with proteins found in the ataxia
network. This study is the ﬁrst that we are aware of in
which patient medical records and a phenotype-based interac-
tome are used together to explore the molecular basis of
comorbid conditions. By interrogating 32 million patient
records, we found that ataxia patients are indeed at increased
risk of any comorbid diagnosis compared with the control
population. Signiﬁcantly, the relative risk of comorbidity
increased from 1.63 to 3.03 when we considered the diseases
represented in the ataxia interactome.
Importantly, the relative risk of 3.03 is likely an underrepre-
sentation of the true comorbidity rate for ataxia and other
diseases represented by the ataxia network. These calculations
are based on currently available data sets. For instance, the
ataxia network is not saturated and thus some interacting pro-
teins are missing by chance. Second, the Medicare patient
records are in the form of ICD-9 codes. These codes do not
correspond in a one-to-one relationship for each disease, but
can correspond to speciﬁc features and symptoms of diseases.
For example, some ICD-9 codes are speciﬁc—such as MD
(code 326.50), whereas some MD cases could instead be
coded as low-vision (codes 369.60, 369.4, 369.3, 369.61 and
others). These potentially overlapping ICD-9 codes can
decrease the power (number of patients) one may see if
some of the overlapping codes are considered together, as
we did with some of the ataxia codes. Conversely, inclusion
of misdiagnosed or miscoded patients can cause false-positive
associations, such as alcohol-induced persisting amnestic dis-
order (code 291.1). Finally, when we account for the liabilities
in our patient records by overlapping comorbid diseases with
the ataxia interactome, we were limited to gene-disease
relationships recorded in OMIM. Unfortunately, OMIM
records are incomplete, even for the associations already
reported in the literature, as exempliﬁed by searching for
MD associations and not ﬁnding ataxin-7 among the results.
Thus, there is a disconnect between a patient having a molecu-
lar diagnosis of, for example, SCA7 and then having medical
records including some form of ataxia and some form of vision
loss. Thus, there are many nuances in patient records and
disease–gene relationship databases that decrease the power
of using a combined molecular and bioinformatics approach
to uncover molecular relationships between comorbid dis-
eases. Despite these limitations, our results show that this
approach is fruitful for identifying these relationships and
such analysis will only improve as electronic medical
records are improved, and more disease-causing genes are
identiﬁed and included into public databases. Furthermore,
the approach and data in this study will serve as a framework
for future studies that will beneﬁt from better electronic
medical data and accurate genetic diagnostic codes.
Overall, our comorbidity analysis and OMIM-based
searches were limited to our ataxia interactome and 13
million patients and yet provided candidate proteins for a
comorbid disease, MD. From these criteria, we found a
highly signiﬁcant subnetwork anchored by three MD causing
proteins. The MD subnetwork contains 32 proteins that may
have a role in MD or macular health. It should be noted that
ataxin-7 is central in this subnetwork. Initially, we were sur-
prised by the fact that many of these MD subnetwork proteins
are predicted to be cytoplasmic or extracellular, however
further literature searches and studies provide strong support
for the biological relevance of this network. Speciﬁcally, 31
of the 32 proteins were previously reported to be expressed
in the retina (65–72,75,78,81,85,87,89,98). EFEMP1, one of
the MD proteins that anchor the network, is a secreted
protein; however, the disease-causing mutation R345W
results in the retention of the protein within the cells
(107,108). In the mammalian retina, EFEMP1 and
ataxin-7 are expressed in the same cell types
(40,46,70,100,107,109,110). Additionally, MEGF8, another
component of the subnetwork, was predicted to be in the cyto-
plasm or extracellular space, but recent studies have demon-
strated that it co-localizes with GFI1B in the nucleus (111).
Given the lack of saturation of this screen and also the lack
of other MD proteins as baits in the screen, it seemed likely
that some or many of the other ataxin-7 interactors that are
not connected to the subnetwork are also involved in
macular health, thus we also included some of these proteins
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selected proteins from within the MD quadruples and other
ataxin-7 interactors are expressed in the mouse retina and
some show altered expression in a mouse model of SCA7.
Thus, we suggest that further investigation of these proteins
could provide valuable insight into age-related MD.
More than 35 transgenic mouse models are available for a
variety of the genes in the MD quadruples. We suggest that
these mice should be further investigated given that mice are
able to freely move, obtain chow and mate without vision,
thus home cage behavior would not be changed even if
these mice have retinal defects. Therefore, it would be inter-
esting to look at the retina and its integrity from these mice
at different ages as well as potential genetic interactions
between seemingly benign mutants and existing models of
retinal degeneration.
In addition to SCA7, there have been several reports of
human diseases and mouse models that involve both cerebellar
or PC and retinal degeneration, including a possible variant of
Boucher–Neuhauser syndrome and PC degeneration (pcd)
mice (112–117), and these cell types express a common
subset of genes (118). Our study shows a systematic under-
lying relationship between ataxia and MD.
Overall, our studies demonstrate that taken together disease-
based interaction networks and patient medical records can
reveal molecular associations underlying comorbidities in
the patient population. Our data provide candidate proteins
for further investigation into the molecular pathogenesis of
SCA6, SCA7 and MD. Additionally, researchers investigating
other diseases represented in the network and comorbid with
ataxia will be able to use the data to interrogate possible mol-
ecular relationships. As researchers continue to develop inter-
action networks based on a common phenotype and medical
records are increasingly made electronic, the power of comor-
bidity analysis to identify common molecular pathways in the
pathogenesis of many diseases will increase too.
MATERIALS AND METHODS
Yeast two-hybrid
Y2H baits were designed based on known homology domains
between species for ataxin-7 and for CACNA1A based on
reports of translocation to the nucleus and splice isoforms
(9,30,38,49). The baits were cloned using Invitrogen
Gateway technology as previously described (15).
Glutathione-sepharose afﬁnity co-puriﬁcations (GST-APs)
Baits were tagged with GST using the Invitrogen Gateway
system as previously described (15,51). Preys were tagged
with myc in the same manner. Prey proteins were ORFeome
clones from the Human ORFeome collection [http://horfdb.
dfci.harvard.edu/ and (119)] or were rescued from the yeast
colonies. Brieﬂy, for yeast rescue, the colony was grown in
liquid culture and lysed. The puriﬁed plasmid was then trans-
formed into E. coli. Since there is no bacterial selection
marker that differs for the bait and prey plasmids in this
system, three to ﬁve colonies were selected and sequenced
to identify the prey colonies. After identiﬁcation, we used
the LR reaction from the Invitrogen Gateway system to trans-
fer the prey coding sequence from the yeast-destination vector
to the entry vector. Using a BP reaction, the coding sequence
was subsequently transferred to the myc-vector as previously
described (15,51).
GST-APs were performed in HEK293T cells. Eight-hundred
nanograms of the GST-bait and myc-prey vectors were trans-
fected into the cells using Lipofectamine 2000 and afﬁnity
puriﬁcations were performed as previously described (15).
Western blots were performed as described previously (15).
Bioinformatic analyses
The sequence data were processed as previously described
(15). Brieﬂy, the sequencing results obtained for the prey
clones from the Y2H screen were submitted to BlastN and
tBlastX searches to identify the protein-coding genes in
NCBI database. The sequence databases used for alignment
analysis were obtained from NCBI. The protein sequence
data for alignments were obtained from ftp://ftp.ncbi.nih.
gov/genomes/H_sapiens/protein/protein.fa.gz, while nucleo-
tide data were obtained from ftp://ftp.ncbi.nih.gov/genomes/
H_sapiens/RNA/rna.fa.gz. The cross-tabulated protein and
nucleotide alignment results were compared (ﬁltered) for
high quality based on E-value as well as for agreement
between the nucleotide and protein result pairs. Discordant
pairs and low-quality results were manually checked and
repaired. Entrez and symbol identiﬁers were determined for
each prey protein passing the alignment ﬁlter. Sequences
that had poor results or questionable BLAST were discarded.
The resulting data were compiled by both bait protein and bait
fragment. A network (undirected graph) was constructed using
the unique bait–prey protein pairs, determined by the analysis
(see below).
Network generation
The network was generated from the published ataxia network
(15) and our screen data. We also included unpublished data
from further rescreening with three of the baits previously
published (15). The ataxia network was drawn using Cytos-
cape (120).
Comorbidity analysis
Medicare patient ICD-9 codes were used to analyze whether
the molecular level gene–disease relationships are also
present in the patient population. The Medicare data set con-
sists of over 32 million hospitalization records of 13 039 018
patients. We ﬁrst removed all patients with a diagnosis of
‘toxic effects of substances chieﬂy nonmedical as to source’
(ICD-9 codes 980–989) from our data set. We then deﬁned
patients as ataxia patients if they had one or more of the fol-
lowing ataxia-related ICD-9 codes in their history: primary
cerebellar degeneration (code 334.2), spinocerebellar disease,
unspeciﬁed (code 334.9), cerebellar ataxia NOS (code
334.3), Friedreich’s ataxia (code 334.0), cerebral ataxia
(code 331.89), ataxia-telangiectasia (code 334.8) and cerebel-
lar ataxia in diseases classiﬁed elsewhere (code 334.4), but not
including patients with alcoholism (codes 303.0–303.9). This
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ataxia. These ataxia patients’ records were searched for other
disease diagnoses (comorbidities). For a given disease, the
relative risk, RR, is measured by
RR =
Cxa
Cxa∗
,
where Cxa is the number of patients that have the disease x and
ataxia (a), and C∗
xa is the expected number of patients that have
disease x and ataxia. The expected comorbidity is C∗
xa¼Ix /N ∗
Ia /N where Ix and Ia are the prevalence of disease x and ataxia,
respectively, and N is the total number of patients. The conﬁ-
dence intervals were measured by the Katz method (121).
Macular degeneration search terms in OMIM
Search terms were: macular corneal dystrophy, MD, macular
dystrophy, maculopathy, retinal cone dystrophy, retinal
degeneration, retinal dystrophy and degeneration of the retina.
In situ hybridization
Probes were designed based on Allen Brain Atlas probes that
were successful in the brain. ISH experiments were performed
as previously described (122–125). Primers used included a
T7 promoter for the sense probe and SP6 promoter for the anti-
sense. Gene-speciﬁc primers are as follows: Atxn7-for 5′-CAC
AGCTATGGAAGAAAATCCC-3′; Atxn7-rev 5′-AGGCTCA
CCGAGTGTGTTTTAT-3′.
Immunoﬂuorescence in wild-type and Ataxin-7
266Q/1 mice
Ataxin-7
266Q/+ and wild-type littermates were sacriﬁced at 5, 8
or 10 weeks in accordance with our approved animal protocol.
Eyes were immediately removed and placed in 4% parafor-
maldehyde in 1xPBS for 1–2 days on a rotator in a cold
room. Tissue was then cryoprotected in a sucrose gradient of
5, 10 and 30 sucrose in 1xPBS overnight at 48. The tissues
were embedded in Tissue-Tek O.C.T Compound (Sakura
Finetek U.S.A., Inc. Torrance, CA 90501, USA) and stored at
2808 until sectioning. Tissue was sectioned on a cryostat at
12 mm,mountedonslidesanddriedovernightatroomtempera-
ture. Slides were stored at 2808 until immunostaining.
Slides were brought to room temperature, washed in PBS
and permeablized with 0.3% Triton X-100 in PBS and
blocked for 2 h at RT with 1% serum, 1% BSA, 0.05%
Triton X-100 in 1xPBS. The slides were washed in PBS and
incubated with the primary antibody (1:200 unless otherwise
noted) without Triton X-100 for 3 days in a humid box at
48. Primary antibodies are: TRIM27 (gtx102048), TRIM23
(gtx100057), CARD10 (gtx111222), SIAH1 (gtx104715),
GRN (gtx100803), RAD23A (gtx100425), Genetex Inc.,
Irvine, CA 92606, USA; GFI1B, D-19 (sc-8559) used at
(1:50), Santa Cruz Biotechnology, Inc., Santa Cruz, CA
95060 USA; and calbindin, D-28K, clone CB-955, (c-9849)
used at (1:500), Sigma-Aldrich, St Louis, MO 63103 USA.
After washing, secondary antibody [goat anti-rabbit Alexa
Fluor 647 (A21245), donkey anti-goat Alexa Fluor 647
(A21447) and goat anti-mouse Alexa Fluor 488 (A11001)
Invitrogen Corporation, Carlsbad, CA 92008 USA] was
added at (1:250) to incubate for 2 days. The slides were
then washed and incubated for 5 min with DAPI (2.5 mg/ml)
in PBS, washed again and mounted with Prolong Gold anti-
fade reagent (P36934), Invitrogen Corporation. After curing,
the slides were stored at 2208 until imaging. Images were
taken on a Leica confocal microscope and processed using
ImageJ software.
For each time point, two to three pairs of mice were col-
lected. Each antibody was used to stain one pair of 5-, 8-
and 10-week-old knock-in and wild-type mice during at least
two independent experiments. Representative images are
selected.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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